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Background: It has been shown that interleukin (IL)-18 levels in induced sputum are reduced in
asthmatic and healthy smokers. However, in chronic obstructive pulmonary disease (COPD)
patients, recent data show an overproduction in the lungs and increased serum levels of
IL-18, suggesting that IL-18 may be involved in the pathogenesis of COPD.
Method: In order to assess the relation of IL-18 with pulmonary function and airway inflamma-
tion in COPD, IL-18, tumour necrosis factor-a, and IL-8 levels were measured by ELISA in
sputum supernatants obtained from patients with bronchitis type COPD (nZ 28), and healthy
subjects (18 smokers and 17 non-smokers). Cellular localization of IL-18 was assessed by immu-
nocytochemistry.
Results: The levels of IL-18 were significantly higher in sputum supernatants of COPD patients
compared to healthy smokers and non-smokers (p< 0.05). IL-18 productionwas localized to sputum
macrophages. IL-18 levels were inversely correlated with FEV1 (% predicted) (rZ 0.572,
pZ 0.002) and FEV1/FVC ratio in COPD smokers (rZ 0.608, pZ 0.001). No correlations were
found between IL-18 levels and inflammatory markers studied in induced sputum obtained from
COPD patients, healthy smokers and non-smokers.
Conclusion: In patientswith COPD, increased levels of IL-18 in induced sputumwere associatedwith
airflow limitation, suggesting that IL-18 may be implicated in the pathogenesis of COPD.
ª 2009 Published by Elsevier Ltd.10 776 3314; fax: þ30 210 723 9127.
a.gr (N. Rovina).
9 Published by Elsevier Ltd.
Raised IL-18 levels in sputum and airflow limitation in COPD 1057Introduction MethodsChronic obstructive pulmonary disease (COPD) is a disease
state characterized by airflow limitation that is not fully
reversible, is usually progressive, and associated with an
abnormal inflammatory response of the lungs.1 Long-term
cigarette smoking is the most important risk factor that
may initiate the disease, as a result of influx of inflam-
matory cells into the lung (leading to chronic airway
inflammation), imbalance between proteolytic and anti-
proteolytic activity, oxidative stress and apoptosis.2
However, there is no effective way as yet to predict the
onset of the disease among smokers, and more importantly,
to treat pulmonary inflammation in COPD, even when
irreversible damage has not yet been established in the
airways or parenchyma.
Cigarette smoking activates the inflammatory cells in
the airways and airway epithelial cells to release inflam-
matory peptides, such as interleukin (IL)-1b, IL-8, inter-
feron (IFN)-a, tumour necrosis factor (TNF)-a, transforming
growth factor (TGF)-b, granulocyte–macrophage colony
stimulating factor, and IL-18.3e5 IL-18, a pro-inflammatory
cytokine originally identified as IL-1b converting enzyme,
has recently been implicated in the pathogenesis of COPD
induced by cigarette smoking, via IL-18Ra dependent sig-
nalling.4 Cigarette smoking induces epithelial apoptosis,
stimulates proteases and chemokines and activates a
variety of caspases via IL-18Ra dependent mechanisms.6e8
IL-18 is produced intracellularly in a wide range of cells
from a biologically inactive precursor, pro-IL-18, by cas-
pase-1.9 It plays an important role in Th1 polarization and
various Th1-type diseases, inducing TNF-a, IL-1b, gran-
ulocyte-macrophage colony-stimulating factor and chemo-
kine production by monocytes and T lymphocytes, whereas
it is now appreciated to be an important regulator of innate
and adaptive immunity.10
In mouse models, it has been shown that constitutive IL-
18 overproduction in the lungs induces emphysema4 and
treatment with recombinant IL-18 plus IL-2 induces
pulmonary inflammation and lung injury.11 The implication
of IL-18 in COPD pathogenesis is further supported by the
fact that IL-18 and its receptor are expressed in human lung
in COPD,12,13 and serum levels of IL-18 are significantly
higher in patients with severe COPD than in healthy
smokers or non smokers.5,13 Most recently, it was demon-
strated that serum levels of IL-18 are negatively correlated
with FEV1 (% pred) in COPD patients,
5 further supporting its
implication in the pathogenesis of COPD. To our knowledge,
there are no studies on IL-18 in sputum obtained from COPD
patients.
Based on the above data, we aimed to identify and
quantify IL-18 levels in sputum samples from healthy and
COPD patients, and furthermore, to evaluate the associa-
tions between IL-18 in induced sputum, pulmonary function
parameters and airway inflammation.
Our results provide the first evidence that IL-18 can be
measured in the sputum of COPD patients, and demon-
strate the clinical relevance of the findings of the previ-
ously conducted animal studies in humans, further
supporting the implication of IL-18 in the pathogenesis of
COPD.Subjects
Twenty-eight COPD smokers, 18 asymptomatic healthy
current smokers and 17 non-smoking controls were included
in the study. All healthy smokers were lifelong smokers (>15
pack-years), with no history of lung disease, no chronic
respiratory symptoms, and normal spirometry. All COPD
patients were current smokers (>15 pack-years), with
chronic cough and sputum production over at least 3 months
for 2 successive years, and irreversible airflow limitation
(reversibility <10% predicted forced expiratory volume in
1 second (FEV1) after 200 mg of inhaled salbutamol). All
patients satisfied the ERS criteria14 for COPD and were
selected to have no evidence of emphysema, based on high-
resolution computed tomographic scans of the lungs and the
diffusing capacity of lung for carbon monoxide (DLCO).
All participants met the following criteria: no use of
inhaled or oral corticosteroids for 6 months prior to sample
collection, no atopy (negative skin prick tests for 10
common aeroallergens), and no respiratory tract infection
1 month prior to the study. None of the COPD patients was
ever hospitalized due to an exacerbation of COPD. Patients
with co-morbidities, such as bronchiectasis, asthma,
interstitial diseases and heart failure, were excluded. None
of the healthy non-smokers and smokers was using long-
acting bronchodilators. Nine out of 28 COPD patients were
under treatment with inhaled tiotropium and inhaled short-
acting b-agonists per need, ten were receiving inhaled
short-acting b-agonists or ipratropium per need, and none
was receiving long-acting bronchodilators. All subjects gave
informed consent for participation in the study, which was
approved by the hospital ethics committee.
Measurements
Lung function tests (flowevolume curves, reversibility test,
diffusing lung capacity for carbon monoxide (DLCO),
measurement of arterial blood gases, skin prick tests, blood
sampling and sputum induction were performed.
Lung function
Lung function (FEV1, FEV1/FVC) was measured with a dry
wedge spirometer (Masterscreen, Jaeger, Hoechberg,
Germany) according to standardized guidelines.15
Measurements were always performed by the same tech-
nician using the same spirometer. Reversibility test was
performed 20 min after inhalation of 200 mg salbutamol via
a metered dose inhaler. Subjects were not allowed to use
short-acting bronchodilators 12 h, and tiotropium 48 h prior
to pulmonary function testing. The diffusing lung capacity
for carbon monoxide (DLCO) was measured by the single-
breath method at least twice (Masterscreen, Jaeger,
Hoechberg, Germany).
Sputum induction and processing
Sputum was induced by inhalation of hypertonic saline
aerosol and processed as described previously.16 Briefly,
Table 1 Subjects’ characteristics.
Healthy
non-smokers
Healthy
smokers
COPD
patients
nZ 17 nZ 18 nZ 28
Age (years) 47  2 49  2 51  2
Smoking (pack-years) 0 45  4 48  6
Sex (male/female) 6/11 8/10 19/9
FEV1 (% pred) 105  3* 100  2* 66  3
FVC (% pred) 107  2* 105  1* 90  3
FEV1/FVC 83  2* 80  18* 60  2
FEF25e75 92  8* 80  5* 30  2
RV (% pred) 99  5 93  3 95  12
TLC (% pred) 94  3 94  2 86  7
FRC (% pred) 94  5 95  4 100  6
DLCO 105  6 83  1 74  15
Arterial PO2 95  8 83  6
COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity;
FEF25e75, forced expiratory flow 25e75; RV, residual volume;
TLC, total lung capacity; FRC, forced residual capacity; DLCO,
diffusing lung capacity for carbon monoxide; PaO2, partial
pressure of oxygen, arterial.
Values are expressed as mean  SE. *p < 0.05, asymptomatic
smokers and healthy non-smokers vs COPD smokers.
1058 N. Rovina et al.15 min after salbutamol inhalation (200 mg), normal saline
0.9% and then hypertonic saline (3%, 4% and 5%) nebulized
by an ultrasonic nebulizer (ULTRA-NEB 2000, DeVilbiss
Healthcare Inc., Somerset, NJ, USA) was inhaled for each
concentration over a period of 7 min. Subjects were
encouraged to cough deeply after the 7-min intervals. All
subjects produced an adequate aliquot of sputum which
was processed within 2 h after termination of the induc-
tion. Sputum samples were transferred to a Petri dish and
the volume and macroscopic characteristics of the whole
sample recorded. Sputum plugs were separated from
contaminating saliva using sterile forceps. The plugs were
placed in a pre-weighed tube and the weight recorded. The
sputum then diluted threefold with phosphate buffer
solution containing freshly prepared dithiothreitol (final
concentration: 1 mmol/l) (Sigma Chemical Co., Poole, UK).
The sample was vortexed briefly and incubated at 37 C for
15 min with constant agitation. The suspension was filtered
through monofilament filter cloth to remove mucus; then
centrifuged at 790  g for 4 min (4 C), and the pellet was
re-suspended. Total cell counts were determined with
a Neubauer haemocytometer (VWR International Ltd,
Poole, UK) using trypan blue exclusion to determine cell
viability; dead cells and epithelial cells were excluded.
Cell sputum preparations were made using cytocen-
trifuge at 500  g for 2 min (Cytospin 3, Shandon Inc,
Pittsburgh, PA, USA). Sputum cytospin slides were stained
with MayeGru¨nwaldeGiemsa for differential cell counts.
Counting of 400 non-squamous cells took place in a blinded
way by one technician. Sputum samples containing >20% of
squamous cells and with cell viability <70% were excluded
from analysis as indication of poor cytospin quality. The
supernatant was stored at 80 C for subsequent assay for
IL-18, IL-8, and TNF-a concentration.
Measurement of IL-18, TNF-a, and IL-8
The concentration of IL-18 in sputum supernatants and
serum was determined by an enzyme-linked immunosor-
bent assay kit (ELISA) (MBL International Corporation)
following the manufacturer’s instructions. The sensitivity of
the assay used was 12.5 pg/ml.
The concentrations of TNF-a and IL-8 were determined
by ELISA as well, using kits purchased from R&D Systems
(Minneapolis, MN, USA). In all cases, the assays were
carried out according to the manufacturer’s recommenda-
tions. The sensitivities of the assays used were 1.6 pg/ml
and 3.5 pg/ml, respectively.
Immunocytochemistry of IL-18 expression
IL-18 localization on sputum cell cytopreparations was
performed as previously described.17 Freshly isolated
sputum cells were centrifuged at 500  g for 2 min (Cyto-
spin 3, Shandon Inc, Pittsburgh, PA, USA), fixed with ice-
cold para-formaldehyde solution 4% (Sigma Chemical Co,
Steinhein, Germany) and stored at 20 C until analysis. On
the day of analysis, slides were thawed and then washed at
room temperature with Tris-buffered saline three times.
Following incubation with blocking buffer (1% BSA in TBS-
0.1% Tween) for 1.5 h, IL-18 was localized using the mouse
monoclonal antibodies IL-18 (1.51 E3E1):sc-13602 (SantaCruz Biotechnology). Bound antibodies were detected with
DakoCytomation Polyclonal Rabbit Anti-Mouse Immuno-
globulins and APAAP. Immunoreactive cells were visualized
by the addition of DAKO Fast Red Substrate after being
lightly counterstained with Harris’ haematoxylin (DAKO,
Glostrup, Denmark). All antibody incubations were con-
ducted at 37 C.
Statistical analysis
Data were expressed in mean (SD) or median values. IL-
18, IL-8, and TNF-a were expressed in median values and
inter-quartile range. Differences between subjects’ groups
were initially assessed by KruskaleWallis test, and if
significant, the ManneWhitney rank test was then assessed.
Correlations between inflammatory cells and mediators in
sputum, smoking characteristics or lung function parame-
ters were calculated with Spearman’s rank correlation test.
Statistical analysis was not influenced by values at the
lower limits of detection since the non-parametric tests
used were based on ranks of values. A p value of less than
0.05 was considered significant.
Results
The clinical characteristics of the subjects participated in
the study are shown in Table 1. All smokers had similar
mean values for age, smoking pack years, arterial oxygen
tension, DLCO (% pred), FRC (% pred), RV (% pred), and TLC
(% pred). However, FEV1, FVC, and FEV1/FVC were signifi-
cantly lower (p < 0.05, Table 1) in COPD smokers compared
to healthy smokers and healthy non-smokers.
Figure 1 Levels of IL-18 (pg/ml), expressed as median values
(inter-quartile range) in induced sputum of healthy non-
smokers, healthy smokers and COPD smokers. *p < 0.05, vs
COPD smokers.
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The median (inter-quartile range) total number of cells in
COPD smokers was higher (p > 0.05) compared to healthy
smokers and significantly higher (p < 0.05) compared to non-
smokers (Table 2). Smokers with COPD had higher
percentage of sputum neutrophils compared to healthy
smokers (p < 0.05), and non-smokers (p < 0.05). In contrast,
the percentage of sputum macrophages was significantly
lower in COPD smokers compared to healthy smokers
(p < 0.05) and non-smokers (p < 0.05) (Table 2).
IL-18 levels in induced sputum
IL-18 levels were higher in the induced sputum of healthy
non-smokers compared to healthy smokers (pZ 0.059). In
the induced sputum samples of COPD smokers IL-18 levels
were significantly higher compared to healthy smokers
(pZ 0.038) and healthy non-smokers (pZ 0.003) (Fig. 1).
IL-18 levels in induced sputum inversely correlated with
FEV1 (% pred) (rZ 0.572, pZ 0.002) and FEV1/FVC
(rZ 0.608, pZ 0.001) in COPD patients (Fig. 2).
No significant correlations between sputum levels of IL-
18 and pulmonary function parameters were observed in
healthy smokers and non-smokers.
IL-8 levels in induced sputum of COPD smokers were
significantly higher compared to healthy smokers
(pZ 0.007) and non-smoking subjects (pZ 0.002), while
TNF-a levels were significantly higher in the induced
sputum of COPD smokers compared to healthy non-smokers
(pZ 0.001) (Table 3). No significant correlations between
IL-18 levels and IL-8 and TNF-a levels were found in any of
the studied groups.
IL-18 localization in sputum cells by
immunocytochemistry
The cellular distribution of IL-18 synthesis was evaluated in
sputum cytospin preparations by immunocytochemistry.
Positive staining was observed in sputum macrophages
(Fig. 3).
Discussion
This study is the first to examine IL-18 levels in the induced
sputum obtained from patients with COPD. Like many
patient-based clinical studies, this is an observational
study, showing that IL-18 levels in the induced sputum ofTable 2 Sputum inflammatory cell numbers in healthy and COP
No. Healthy non-smokers
nZ 17
Total no of cells 104 28 (8e43)
Macrophages, % 56 (13e86)
Neutrophils, % 41 (12e79)
Lymphocytes, % 0.6 (0.2e1)
Eosinophils, % 0.9 (0.3e0.6)
Values are median (inter-quartile range). *p < 0.05 vs healthy non smCOPD patients are significantly higher compared to healthy
smokers and non-smokers. The levels were correlated with
airflow limitation in COPD patients.
The finding of elevated IL-18 levels in the sputum of
COPD patients may not be surprising taking in account the
results of previously published data on COPD.4,5,13 IL-18,
a member of IL-1 family, was originally described as IFN-g-
inducing factor (IGIF) and is appreciated to be an important
regulator of innate and adaptive immunity.10 Cigarette
smoke is the major cause of COPD and it has a well-known
ability to modulate innate immunity either by increasing
the number of innate immune effectors such as neutrophils
and macrophages in the lung or by regulating macrophage
function and the expression of genes involved in innate
immune responses.18e21 It is appreciated that innate
immune response plays a particularly important role in the
pathogenesis of the inflammatory and remodelling
responses in CS-exposed individuals.22 Very recently, Kang
et al.23 demonstrated that the interaction of CS with
inflammatory, remodelling, and apoptotic responses is
associated with the early induction of type I IFNs and IL-18,
later induction of IL-12/IL-23 p40 and IFN-g, and the acti-
vation of PKR and eIF2a offering a new window of oppor-
tunity for a better understanding of the unique interactionD smokers as compared to healthy non-smokers.
Healthy smokers COPD patients
nZ 18 nZ 28
37 (30e115) 62 (18e233)*
48 (38e62)# 32 (10e84)*
48 (8e59)# 62 (17e92)*
2 (0.6e5.5) 2.5 (0.41e4.4)
0.32 (0.1e1.9) 1.2 (0.25e2.2)
okers, #p < 0.05 vs healthy smokers.
Figure 2 Spearman’s rank correlation: IL-18 levels and lung function in bronchitis type of COPD smokers (nZ 28) (GOLD
stages IeII).
1060 N. Rovina et al.between cigarette smoke and innate immune responses and
the role of IL-18 in this procedure.
Themost potent explanation to consider for the finding of
the elevated IL-18 levels in induced sputum obtained from
COPD patients might be the bacterial colonization of the
bronchial tree. Bacterial colonization of distal airways is
frequently found in patients with stable COPD and several
risk factors have been found to influence it (smoking, airway
obstruction severity, airway inflammation).24,25 It has
recently been shown that Haemophilus influenzae is
frequently present in the airways of COPD patients during
clinically stable periods.25,26 forming biofilms on airway
epithelia.27 These biofilms cause the release of proin-
flammatory cytokines and chemokines by airway epithelia.
Previous studies reported that H. influenzae stimulates
respiratory epithelial production of macrophage-inflamma-
tory proteins, IL-8, and TNF-a in cell culture and mouse
models.28 These data support the idea that airway epithelia
play key roles in innate immunity and may help to signal and
coordinate both innate and adaptive immune responses. This
scenario could probably explain the decreased levels of IL-18
found in induced sputum obtained from asthmatic and
healthy smokers in contrast to COPD patients,29 and pose the
distinct role IL-18 may play in COPD as compared to asthma.
Age as a factor up-regulating IL-18 levels in the sputum
of COPD patients could not be the issue in this study since
all the subjects enrolled did not differ significantly in age.
Nevertheless, no correlation was found between IL-18
levels in sputum and the age of the subjects in any of theTable 3 IL-8 and TNF-a levels in induced sputum.
Healthy
non smokers
Asymptomatic
smokers
COPD
smokers
nZ 17 nZ 18 nZ 28
Sputum IL-8
(ng/ml)
0.7 (0.3e4.6) 1.3 (0.6e30.6)#6.2 (0.9e38)*
Sputum TNF-a
(pg/ml)
14 (0.5e35) 21 (1.5e173) 53 (3.5e210)*
Values are median (inter-quartile range), *p < 0.05 vs non
smokers, #p < 0.05 vs smokers.studied groups. To the authors’ knowledge there is no
reference in the literature concerning the variation of IL-18
levels in sputum with age.
In the present study, as set in the inclusion criteria,
COPD patients were stable, actually never hospitalized for
an exacerbation, and were not on ICS treatment that
modulates bronchial inflammation. All the above criteria,
however, do not diminish the possibility of a bacterial
colonization scenario to be the major factor contributing to
the elevated levels of IL-18 in induced sputum. However,
further analysis is needed to clarify whether airway
bacterial colonization along with cigarette smoking or COPD
per se is the cause for increased IL-18 levels in the induced
sputum of COPD patients.
Immunocytochemistry localized IL-18 expression to
sputum macrophages. It has been suggested that IL-18 is
probably produced directly by the sputum cells; however,
bronchial epithelium may also contribute to the IL-18
detected in sputum.4 In bronchitis type COPD, which is the
studied group here, airway inflammation is characterized
by an influx of inflammatory cells, predominantly neutro-
phils, macrophages, and CD8þ T lymphocytes, into the
airway walls.30e32 In the present study, higher number of
inflammatory cells, percentage of neutrophils and levels of
IL-8 and TNF-a were demonstrated in the induced sputum
of COPD smokers compared to healthy smokers, in
concordance with our previous observations.33e35 It is sug-
gested by the authors that in line with the findings in the
lung biopsies where IL-18 is strongly expressed in alveolar
macrophages and CD8þ T cells, in the airways the majority
of CD8þ T cells and activated macrophages produce IL-18.5
In this study, an inverse correlation was found between
IL-18 levels and FEV1 (% pred) and FEV1/FVC ratio in COPD
patients. This finding is additive to the first evidence shown
by Imaoka and colleagues5 in severe COPD, where IL-18
levels in the sera were inversely correlated with % FEV1.
Our findings further support the association between
increased IL-18 levels and airflow limitation in COPD
patients, suggesting that IL-18 might be used as a new
biomarker for disease activity and progression.
None of the COPD patients who participated in this study
had been receiving inhaled or systemic steroid therapy. The
Figure 3 Immunocytochemistry of IL-18 in sputum cells. IL-18 was localized using mouse monoclonal antibodies IL-18. Bound
antibodies were detected with Polyclonal Rabbit Anti-Mouse Immunoglobulins and APAAP. Immunoreactive cells were stained
brown. Staining was observed only in sputum macrophages. Images are shown at magnification 400.
Raised IL-18 levels in sputum and airflow limitation in COPD 1061treatment received by COPD patients consisted mainly of
the use of bronchodilators, such as b2-agonists and anti-
cholinergics which do not alter airway inflammation. Up to
now, there is no effective therapy to reduce the persistent
pulmonary inflammation in COPD patients and improve
their prognosis.36,37 Therefore, the disease has to be tar-
geted with new anti-inflammatory treatments. Our results
further support the possibility raised by previous studies
that blockade of the IL-18 pathway might be a feasible
therapeutic target in COPD.
In conclusion, elevated levels of IL-18 in induced sputum
of COPD smokers in combination with the close correlation
of IL-18 levels with airflow limitation in bronchitis type
COPD patients support the implication of IL-18 in the
pathologic changes occurring in bronchial epithelium quite
early in COPD patients’ airways. If this is proven to be true,
then IL-18 levels in induced sputum could be used as a valid
biomarker for disease activity and progression, and the IL-
18 pathway could be considered as a potential therapeutic
target for COPD.
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